CorAssist

Company Overview

Snapshot

Founded in January 2003 by Yotam Reisner, Shay Dubi, and Yair Feld, CorAssist operated with 1–10 employees. The company raised $14.5 million across 4 funding rounds from 7 investors. In September 2008, CorAssist initiated human trials for its cardiac device.

Business overview

CorAssist was a clinical-stage medical device company focused on developing therapeutic products for treating heart failure with preserved ejection fraction. The company's proprietary technology involved implantable devices designed to directly improve cardiac diastolic function. Its product portfolio included CORolla, an elastic, self-expanding, internal, spring-like device implanted inside the left ventricle, and ImCardia, an elastic, self-expanding device attached to the external left ventricular surface. CorAssist operated within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics markets, serving patients and healthcare providers in the United States and Israel.

Company Intelligence Q&A

What was CorAssist's primary focus?

CorAssist developed therapeutic products for treating heart failure with preserved ejection fraction, utilizing proprietary technology to improve cardiac diastolic function.

When did CorAssist begin human trials for its cardiac device?

In September 2008, CorAssist initiated human trials for its cardiac device.

What was the total capital raised by CorAssist?

CorAssist raised a total of $14.5 million across 4 funding rounds.

Which investors participated in CorAssist's March 2009 funding round?

In March 2009, CorAssist received funding from Aurum Ventures M.K.I and Evergreen Venture Partners.

What was the status of CorAssist?

CorAssist is a Non Active company, having ceased operations in December 2022.